| Product NDC: | 25021-115 | 
| Proprietary Name: | Clindamycin | 
| Non Proprietary Name: | Clindamycin Phosphate | 
| Active Ingredient(s): | 150 mg/mL & nbsp; Clindamycin Phosphate | 
| Administration Route(s): | INTRAVENOUS | 
| Dosage Form(s): | INJECTION, SOLUTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 25021-115 | 
| Labeler Name: | Sagent Pharmaceuticals | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | ANDA090109 | 
| Marketing Category: | ANDA | 
| Start Marketing Date: | 20120515 | 
| Package NDC: | 25021-115-51 | 
| Package Description: | 1 BOTTLE in 1 CARTON (25021-115-51) > 60 mL in 1 BOTTLE | 
| NDC Code | 25021-115-51 | 
| Proprietary Name | Clindamycin | 
| Package Description | 1 BOTTLE in 1 CARTON (25021-115-51) > 60 mL in 1 BOTTLE | 
| Product NDC | 25021-115 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | Clindamycin Phosphate | 
| Dosage Form Name | INJECTION, SOLUTION | 
| Route Name | INTRAVENOUS | 
| Start Marketing Date | 20120515 | 
| Marketing Category Name | ANDA | 
| Labeler Name | Sagent Pharmaceuticals | 
| Substance Name | CLINDAMYCIN PHOSPHATE | 
| Strength Number | 150 | 
| Strength Unit | mg/mL | 
| Pharmaceutical Classes | Decreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [Chemical/Ingredient] |